BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

Post-LOE

bismuth subsalicylate; metronidazole; tetracycline hydrochloride

R-Pharm US

ANDAORALTABLET, CHEWABLE, TABLET, CAPSULE

Approved

Nov 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE (bismuth subsalicylate; metronidazole; tetracycline hydrochloride) by R-Pharm US. Approved for travelers' diarrhea diarrhea upset stomach due to overindulgence in food, drink, including: heartburn indigestion nausea gas belching fullness. First approved in 2018.

Drug data last refreshed 19h ago

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications (3)

travelers' diarrhea diarrhea upset stomach due to overindulgence in food drink

Worked on BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.